VCEL: Vericel Corp. Price to Sales

Symbol and logo of brand Vericel Corp (VCEL)

Vericel Corporation (VCEL) maintains a leading position in tissue and skin regeneration, which drives its price action, with the price-to-sales ratio 9.10 representing the latest metric reading. Innovations in cartilage therapy and the expansion of insurance coverage support this growth. The company's proprietary production of bioproducts, combined with optimized biopsy logistics, ensures reliability. Analyzing this indicator helps assess whether the stock is overbought relative to the company's actual sales volumes.

VCEL: Vericel P/S Multiple 07/04/2022 - 11/13/2026

Analytical breakdowns for Vericel Corp. (VCEL)

- current price and projected stock value:
Price Chart vcel.com|VCEL - Analyst Consensus Forecast
- market capitalization information:
Market Value Vericel Corp.|VCEL - Total Company Value
- shareholders' equity book value data:
Accounting Value of a Share Vericel|VCEL - Book Capitalization|Market Capitalization to Book Value vcel.com|VCEL - Company Total Assets
- issuer credit burden and liquidity indicators:
Total Debt to Equity Ratio Vericel Corporation|VCEL - Long-Term Debt to Capital|Current Liabilities to Capital Vericel Inc.|VCEL - Company Debts|Debt to Book Capitalization Ratio Vericel Corp.|VCEL - Company Long-Term Liabilities|Company Short-Term Loans and Borrowings Vericel|Quick Liquidity Indicator vcel.com
- earnings and valuation multiples information:
VCEL - Company Net Income|Expected Net Profit Vericel Corporation|VCEL - Price to Earnings Ratio|Future Price to Earnings Multiple Vericel Corp|VCEL - Price/Earnings to Growth Ratio|Company Value to Operating Income Before Depreciation Ratio Vericel Corp.|VCEL - Profit before payment of interest, taxes and amortization|Net earnings per one share for the last twelve months Vericel|VCEL - Earnings per share for the last twelve months|Year-over-year earnings per one share growth for the last 12 months vcel.com|VCEL - Earnings growth in current year|Earnings growth forecast for next year Vericel Corporation
- issuer revenue and sales details:
VCEL - Company Sales|Company Projected Revenue Volume vcel.com|VCEL - P/S Multiple|Market Cap to Expected Sales Ratio Vericel Corp.
Fundamental company analysis:vcel.com VCEL
Original product of Vericel

Vericel Corporation (VCEL) narrow specialization in high-cost cell therapy makes its revenue sensitive to demand for specific products, which directly impacts the business's market value. By analyzing the company's P/S ratio, an investor determines the price of one dollar of sales, assessing whether the current capitalization is justified by the expansion rate of the development portfolio and historical asset valuation cycles.

Who Vericel Corporation competes with

Price-to-Revenue Ratio KRYS (krystalbio.com)|P/S Multiple APGE (Apogee Therapeutics, Inc.)|Arcutis (ARQT) - Price to Sales|ORKA - Price-to-Revenue Ratio|Market Capitalization-to-Revenue Ratio SMTI (Sanara MedTech Inc.)|DBVT: P/S Multiple|SLSN - Price-to-Revenue Coefficient|DERM (Journey Medical Corp) - P/S Multiple|Market Cap to Revenue Forte Biosciences Inc. (FBRX)|P/S Multiple EMPG|SLGL - Price to Sales|Price-to-Revenue Ratio AXIL Brands AXIL|medicuspharma.com - Price-to-Revenue Ratio|VRCA: Market Cap to Revenue|Market Capitalization-to-Revenue Ratio HOTH (Hoth Therapeutics, Inc.)|BFRI: P/S Multiple|Market Cap to Revenue VYNE Therapeutics Inc.|Price-to-Revenue Ratio Sonoma Pharmaceuticals Inc.|Price to Sales Quoin Pharma QNRX|Price-to-Revenue Ratio Azitra (AZTR)|DRMA (Dermata Therapeutics Inc) - Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Elevai Skincare ELAB|RVNC (Revance Therapeutics Inc) - Price-to-Sales Ratio